Showing results (541-550 of 844) with videos related to
Sort By:
Pageof 85
Cancer|February 25, 2003
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia, Susan Murray, Karen Price, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancerS Gelber, A S Coates, A Goldhirsch, et al.Cancer Treatment Reviews|May 1, 2012
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trialsJanaina Brollo, Giuseppe Curigliano, Davide Disalvatore, et al.British Journal of Cancer|October 23, 2008
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activityR Torrisi, V Bagnardi, A Cardillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus BevacizumabAngelica Calleri, Anna Bono, Vincenzo Bagnardi, et al.International Journal of Radiation Oncology, Biology, Physics|August 24, 2010
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapyPer Karlsson, Bernard F Cole, Marco Colleoni, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)L Perey, R Paridaens, H Hawle, et al.Breast Care (Basel, Switzerland)|August 3, 2018
Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II TrialEmilia Montagna, Vincenzo Bagnardi, Giuseppe Cancello, et al.Breast (Edinburgh, Scotland)|February 2, 2010
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancerMonica Iorfida, Vincenzo Bagnardi, Alessandra Balduzzi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2005
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancerO Pagani, C Sessa, F Nolè, et al.Pageof 85